

**CMP: INR 179**

**Rating: HOLD**

**Target Price: INR 196**

**Stock Info**

|                  |                  |
|------------------|------------------|
| BSE              | 500477           |
| NSE              | ASHOKLEY         |
| Bloomberg        | AL:IN            |
| Reuters          | ASOK.NS          |
| Sector           | Auto-LCVS & HCVS |
| Face Value (INR) | 1                |
| Mkt Cap (INR Bn) | 1024.4           |
| 52w H/L (INR)    | 215/125          |


**Shareholding Pattern %**

(As on June, 2026)

|           |       |
|-----------|-------|
| Promoters | 51.51 |
| Public    | 20.67 |
| DII       | 15.75 |
| Others    | 12.06 |

| Stock Performance (%) | 1m   | 6m    | 12m  |
|-----------------------|------|-------|------|
| Ashok Leyland         | 11.2 | -16.2 | 41.5 |
| Nifty                 | 1.3  | -5.1  | -1.1 |

**Ashok Leyland Vs Nifty**



**Abhishek Jain**

[Abhishek.jain@arihantcapital.com](mailto:Abhishek.jain@arihantcapital.com)  
022-42254827

**Ashvath Rajan**

[Ashvath.rajan@arihantcapital.com](mailto:Ashvath.rajan@arihantcapital.com)  
022-42254870

Ashok Leyland Ltd reported Q1FY27 numbers revenue stood at INR 95,828 Mn (+10.4% YoY/-31.9% QoQ); below our estimate of INR 95,828 Mn. EBITDA for the quarter stood at INR 9,695 Mn (flat YoY/-53.1% QoQ); below our estimate of INR 12,100 Mn. EBITDA margin stood at 10.1% (-105bps YoY/-456bps QoQ) below our estimate of 12.4%. PAT stood at INR 6,091 Mn (+2.6% YoY/-56.6% QoQ); below our estimate of INR 7,352 Mn. PAT Margin reported at 6.4% below our estimate of 7.5% (-48bps YoY/-362bps QoQ).

**Near-term margin pressure, but recovery remains intact**

Q1FY27 EBITDA margin declined 100bps YoY to 10.1%, as raw material costs increased 90bps YoY to 71.5% of revenue due to commodity inflation and supply chain disruptions. While management expects commodity pressure to remain challenging in Q2, Q3-Q4 is expected to display recovery. The company is mitigating the impact through pricing, cost savings, product/business mix and inventory management. Management indicated that the ~1.2-1.25% price increase during Q1, along with cost savings and inventory benefits, offset a significant portion of commodity inflation. We expect margin recovery to remain back-ended, with operating leverage, mix improvement and improvement in commodity pressure supporting EBITDA margin expansion from FY27E to FY29E.

**CV demand continues to remain strong**

The domestic CV industry remains on a healthy growth trajectory, with MHCV industry volumes growing 13% YoY and LCV VAHAN volumes increasing 17% YoY in Q1FY27 despite geopolitical and supply-chain headwinds. Ashok Leyland outperformed the industry, with domestic MHCV truck volumes growing 15% YoY to 22,998 units, while LCV offtake increased 21% YoY to 18,874 units, the highest-ever Q1 volume for its LCV business. Domestic MHCV market share stood at 29%, while LCV VAHAN market share improved 30bps YoY to 13.2%. We expect the company's broad product portfolio and continued network expansion to support further share gains, particularly in the LCV and higher-HP MHCV segments.

**Non-CV provides additional growth levers**

The company's non-CV businesses continue to scale, reducing dependence on the core domestic truck business. Domestic aftermarket revenue grew 12.7% YoY, while Power Solutions and Defence revenues increased 51% and 64%, respectively, in Q1FY27. Switch Mobility delivered 225 electric buses and ~300 electric LCVs during the quarter and has a healthy 2,100 electric-bus order book following a recent 650-bus order win. Hinduja Leyland Finance also reported 20% YoY growth in AUM to INR60,310 crore, with PAT increasing 37% YoY. We expect the scaling of these businesses to provide incremental growth and improve the overall earnings mix over the medium term.

**Robust Non-Vehicle and Defence Order Pipelines**

AL's Defence business continued to scale up, with revenue growing 64% YoY in Q1FY27. Management indicated that the defence order book and tender pipeline remain strong, providing visibility for sustained growth as the company executes on existing orders. Defence is also emerging as an important diversification lever, with significant headroom to expand the business given its relatively higher margin opportunity. We expect increasing execution of defence orders, alongside a healthy tender pipeline, to support growth in the non-CV portfolio and gradually improve the company's overall earnings mix.

**Outlook and valuation**

We remain positive on the medium-term CV cycle, supported by healthy industry demand, replacement requirements and Ashok Leyland's continued market-share gains. However, near-term profitability is likely to remain under pressure from elevated commodity costs, with management indicating that Q2 could remain challenging before an improvement from Q3/Q4. We expect volume growth, higher realizations, premiumization and gradual margin recovery to drive earnings growth over FY27-29E. We estimate revenue/EBITDA/PAT CAGR of ~10.6%/13.5%/14% over FY27E-FY29E, with EBITDA margin improving from 13.3% in FY27E to 14.0% by FY29E based on our current estimates. We maintain our HOLD rating and value Ashok Leyland on an SOTP basis, assigning 20x FY28E EPS of INR 9.1 to the core business while factoring in INR ~16/share for HLF, arriving at a target price of INR 198.

| Quarterly Results           |         |          |         |         |         |
|-----------------------------|---------|----------|---------|---------|---------|
| Standalone (INRm)           | Q1FY27  | Q4FY26   | Q1FY26  | QoQ%    | YoY%    |
| Revenue                     | 95,828  | 1,40,750 | 86,815  | -31.9%  | 10.4%   |
| Other operating income      | 516     | 855      | 430     | -39.7%  | 19.8%   |
| Net Sales                   | 96,344  | 1,41,605 | 87,245  | -32.0%  | 10.4%   |
| Cost of material consumed   | 69,206  | 95,355   | 63,866  | -27.4%  | 8.4%    |
| Purchases of stock-in-trade | 4,769   | 4,851    | 4,271   | -1.7%   | 11.7%   |
| Changes in inventories      | (5,052) | 847      | (6,509) | -696.4% | -22.4%  |
| Raw Material                | 68,924  | 1,01,053 | 61,628  | -31.8%  | 11.8%   |
| Staff Cost                  | 6,927   | 7,216    | 6,122   | -4.0%   | 13.2%   |
| Other expenditure           | 10,797  | 12,681   | 9,799   | -14.9%  | 10.2%   |
| Total Expenditure           | 86,648  | 1,20,950 | 77,550  | -28.4%  | 11.7%   |
| EBITDA                      | 9,695   | 20,655   | 9,696   | -53.1%  | 0.0%    |
| Depreciation                | 1,829   | 1,826    | 1,828   | 0.2%    | 0.1%    |
| EBIT                        | 7,866   | 18,829   | 7,867   | -58.2%  | 0.0%    |
| Interest                    | 415     | 421      | 419     | -1.3%   | -0.8%   |
| Other Income                | 851     | 683      | 529     | 24.6%   | 61.0%   |
| PBT                         | 8,302   | 19,091   | 7,977   | -56.5%  | 4.1%    |
| Exceptional items           | -       | -        | -       | -       | -       |
| PBT                         | 8,302   | 19,091   | -       | -       | -       |
| Current Tax                 | 2,118   | 4,998    | 1,940   | -57.6%  | 9.2%    |
| Deferred tax                | 93      | 46       | 100     | 101.7%  | -7.2%   |
| Tax                         | 2,211   | 5,044    | 2,040   | -56.2%  | 8.4%    |
| PAT                         | 6,091   | 14,047   | 5,937   | -56.6%  | 2.6%    |
| Extraordinary               | -       | -        | -       | -       | -       |
| Reported PAT                | 6,091   | 14,047.2 | 5,937.3 | -56.6%  | 2.6%    |
| EPS                         | 1.04    | 2.39     | 1.01    | -56.5%  | 3.0%    |
|                             |         |          |         |         |         |
| Margins                     | Q1FY27  | Q4FY26   | Q1FY26  | QoQ%    | YoY%    |
| Gross margins               | 28.5%   | 28.6%    | 29.4%   | -18Bps  | -90Bps  |
| EBITDA                      | 10.06%  | 14.59%   | 11.1%   | -452Bps | -105Bps |
| PAT                         | 6.3%    | 9.9%     | 6.8%    | -360Bps | -48Bps  |
| Effective Tax Rate          | 26.6%   | 26.4%    | 25.6%   | 21Bps   | 106Bps  |
| Cost Analysis               |         |          |         |         |         |
| RM/Net Sales                | 71.54%  | 71.36%   | 70.64%  | 18Bps   | 90Bps   |
| Other Exp/Net Sales         | 11.21%  | 8.96%    | 11.23%  | 225Bps  | -38Bps  |
| Staff cost/Netsales         | 7.19%   | 5.10%    | 7.02%   | 209Bps  | 17Bps   |
|                             |         |          |         |         |         |
| Volume (In Units)           | Q1FY27  | Q4FY26   | Q1FY26  | QoQ%    | YoY%    |
| MHCV                        | 27,428  | 42,335   | 26,635  | -35.2%  | 3.0%    |
| LCV                         | 18,874  | 16,416   | 17,697  | 15.0%   | 6.7%    |
| Total Sales                 | 46,302  | 58,751   | 44,332  | -21.2%  | 4.4%    |
| EXPORT                      | 65,176  | 75,167   | 62,029  | -13.3%  | 5.1%    |
| M&HCV                       | 1,996   | 4,158    | 4,083   | -52.0%  | -51.1%  |
| LCV                         | 465     | 6,549    | 701     | -92.9%  | -33.7%  |
| Total Exports               | 2,461   | 10,707   | 4,784   | -77.0%  | -48.6%  |
| Total Volume                | 48,763  | 69,458   | 49,116  | -29.8%  | -0.7%   |

Source: Arihant Research, Company Filings

**Volume & Market Share:** Ashok Leyland's Q1FY27 volumes stood at 48,673 units, while revenue increased 10% YoY to INR 96,340 Mn. Domestic MSCV market share remained at 29%, while LCV market share improved by 30bps YoY to 13.2%. Industry momentum improved through the quarter, with June and July recording ~20% growth after a relatively weak May. Management expects domestic MSCV industry volumes to grow at high-single digits in FY27, with LCV growth expected to be marginally higher.

**Margin Trajectory** Q1FY27 EBITDA stood at INR 9,700 Mn, translating into a 10.1% margin, with material costs at 71.5% of revenue. Management expects commodity inflation to peak in Q2FY27 and moderate thereafter, with greater cost relief expected in Q4. Price increases of ~2.25% in MSCV and ~3.5% in LCV during FY27, along with product mix improvement and the 2K cost-reduction programme, should partly offset input-cost inflation. The pace of commodity moderation and price absorption remain key margin monitorables.

**Defence and EV businesses:** The Defence business recorded 64% YoY revenue growth in Q1FY27, with the order book and tender pipeline remaining active. Switch Mobility has an order book of 2,100 electric buses, having delivered 225 buses and nearly 300 LCVs during the quarter, while OHM Mobility is progressing towards PAT break-even. These businesses remain relatively early-stage contributors, with execution and profitability improvement being key to their contribution to consolidated earnings.


**LCV Portfolio:** Ashok Leyland plans to expand its presence across the LCV range, beyond its historical participation in ~50% of the segment. A broader product portfolio should increase the company's addressable market and provide scope for further market share gains as LCV demand improves. The 13.2% LCV market share in Q1FY27, up 30bps YoY, provides an initial indication of progress.

**International Business:** GCC volumes remained affected by logistical issues in the UAE, although management expects a recovery through the year. The company is accelerating its Saudi Arabia plant and is evaluating ASEAN as its fourth home market. These initiatives should broaden Ashok Leyland's international presence, although near-term contribution from the new markets is likely to remain limited.

**Strong balance Sheet:** Ashok Leyland remained in a net cash position of INR 22,520 Mn, up INR 4,310 Mn YoY. Q1FY27 capex stood at INR 15,330 Mn, with investments directed towards future technologies, alternate powertrains and EVs. Full-year capex is expected at INR 9,000–10,000 Mn, while the company plans to support Switch Mobility through USD 25 Mn of debt repayment in FY27. The balance sheet provides flexibility to fund ongoing investments without materially constraining financial capacity.

**Replacement Demand:** Management remains constructive on the underlying CV demand environment, supported by the 6.7% GDP growth outlook and replacement demand from ageing BS3/BS4 fleets. The company does not expect BS7 implementation for Indian CVs before 2031-32, limiting the near-term risk of regulatory-driven product transition costs. Industry volume recovery and replacement demand remain the key drivers for the medium-term CV cycle.

**Exhibit 5: EBITDA/Vehicle expected to increase in Q3/Q4**



| P&L (INR mn) Standalone                  | FY26          | FY27E         | FY28E         | FY29E         |
|------------------------------------------|---------------|---------------|---------------|---------------|
| Net sales                                | 440,070       | 471,542       | 521,870       | 576,643       |
| YoY (%)                                  | 13.6          | 7.2           | 10.7          | 10.5          |
| Raw material cost                        | 314,171       | 336,209       | 370,528       | 405,957       |
| Employee Cost                            | 26,067        | 29,977        | 34,473        | 38,955        |
| Admin Expenses                           | 42,510        | 42,439        | 45,925        | 50,745        |
| Total expenses                           | 382,748       | 408,625       | 450,926       | 495,657       |
| EBIDTA                                   | 57,322        | 62,917        | 70,944        | 80,987        |
| (%)                                      | 13.0%         | 13.3%         | 13.6%         | 14.0%         |
| Depreciation                             | 7,152         | 8,887         | 9,797         | 10,707        |
| EBIT                                     | 50,171        | 54,030        | 61,147        | 70,280        |
| Interest                                 | 1,697         | 682           | 490           | 294           |
| Other income                             | 3,152         | 3,215         | 3,279         | 3,345         |
| PBT                                      | 51,625        | 56,563        | 63,937        | 73,331        |
| Exchange gain / (loss) on swap contracts | -             | -             | -             | -             |
| (-) Tax                                  | 12,485        | 15,486        | 17,477        | 20,014        |
| Tax/ PBT                                 | 24.2          | 27.4          | 27.3          | 27.3          |
| <b>PAT</b>                               | <b>39,140</b> | <b>41,077</b> | <b>46,459</b> | <b>53,317</b> |
| YoY (%)                                  | 22.3          | 4.9           | 13.1          | 14.8          |
| PAT(%)                                   | 8.9%          | 8.7%          | 8.9%          | 9.2%          |
| Extraordinary                            | -             | -             | -             | -             |
| <b>Reported Profit</b>                   | <b>39,140</b> | <b>41,077</b> | <b>46,459</b> | <b>53,317</b> |

| B/Sheet (INR mn) Standalone | FY26           | FY27E          | FY28E          | FY29E          |
|-----------------------------|----------------|----------------|----------------|----------------|
| Equity capital              | 5,874          | 5,874          | 5,874          | 5,874          |
| Reserves                    | 125,260        | 136,515        | 149,245        | 163,854        |
| Net worth                   | 131,134        | 142,389        | 155,119        | 169,728        |
| Total Loans                 | 11,950         | 9,026          | 6,044          | 3,001          |
| Deferred Tax                | 5,357.10       | -              | -              | -              |
| <b>Total Liabilities</b>    | <b>148,441</b> | <b>151,415</b> | <b>161,162</b> | <b>172,729</b> |
| Gross block                 | 129,722        | 143,722        | 157,722        | 171,722        |
| Less: Acc. Dep              | 59,587         | 68,474         | 78,271         | 88,978         |
| Net block                   | 70,134         | 75,247         | 79,450         | 82,744         |
| Work in progress            | 2,100          | 2,100          | 2,100          | 2,100          |
| Investments                 | 69,206         | 65,993         | 66,393         | 66,793         |
| Inventories                 | 40,786         | 41,450         | 45,681         | 50,049         |
| Debtors                     | 29,504         | 38,757         | 42,893         | 47,395         |
| Cash                        | 22,771         | 4,787          | (790)          | 5,441          |
| Loans and advances          | 17,141         | 40,153         | 54,616         | 60,094         |
| Current assets              | 110,202        | 125,147        | 142,401        | 162,980        |
| Current liabilities         | 94,383         | 99,993         | 110,279        | 121,001        |
| Provisions                  | 8,817          | 17,080         | 18,903         | 20,887         |
| Net current assets          | 7,001          | 8,075          | 13,219         | 21,093         |
| <b>Total Assets</b>         | <b>148,441</b> | <b>151,415</b> | <b>161,162</b> | <b>172,729</b> |

Source: Arihant Research, Company Filings

| Cash Flow Standalone | FY26          | FY27          | FY28E         | FY29E         |
|----------------------|---------------|---------------|---------------|---------------|
| Net profit           | 35,655        | 41,077        | 46,459        | 53,317        |
| Depreciation         | 7,152         | 8,887         | 9,797         | 10,707        |
| Deferred tax         | 214           | 214           | 214           | 214           |
| Change in W/C        | -6,503        | -18,558       | -10,224       | -1,144        |
| Operating cash flow  | 36,519        | 31,619        | 46,247        | 63,094        |
| Capex                | -11,331       | -14,000       | -14,000       | -14,000       |
| Investments          | -1,545        | -273          | -401          | -401          |
| Investing cash flow  | -12,876       | -14,273       | -14,401       | -14,401       |
| <b>FCF</b>           | <b>25,187</b> | <b>17,619</b> | <b>32,247</b> | <b>49,094</b> |
| Dividend             | #VALUE!       | -29,822       | -33,730       | -38,708       |
| Equity               | #VALUE!       | 0.00          | (0.00)        | -             |
| Debt                 | -2,867        | -2,924        | -2,983        | -3,042        |

| Key Ratios              | FY26 | FY27E | FY28E | FY29E |
|-------------------------|------|-------|-------|-------|
| EPS                     | 6.7  | 7.0   | 7.9   | 9.1   |
| Cash EPS                | 7.3  | 8.5   | 9.6   | 10.9  |
| Book value              | 22   | 24    | 26    | 29    |
| P/E (x)                 | 30.9 | 29.4  | 26.0  | 22.7  |
| EV/EBDITA (x)           | 19.7 | 18.2  | 16.2  | 14.1  |
| P/B (x)                 | 9.2  | 8.5   | 7.8   | 7.1   |
| EV/Sales                | 1.4  | 1.2   | 1.2   | 1.1   |
| ROCE                    | 28%  | 29%   | 27%   | 29%   |
| ROE                     | 32%  | 32%   | 29%   | 30%   |
| Dividend Yield          | 3.0% | 1.8%  | 2.0%  | 2.2%  |
| Gross asset turn        | 3.1  | 3.1   | 3.1   | 3.3   |
| <b>Days outstanding</b> |      |       |       |       |
| Inventory               | 47   | 45    | 45    | 45    |
| Debtors                 | 24   | 30    | 30    | 30    |
| Creditors               | 91   | 90    | 90    | 90    |

Source: Arian Research, Company Filings

## Arihant Research Desk

Email: [instresearch@arihantcapital.com](mailto:instresearch@arihantcapital.com)

Tel. : 022-42254800

| Head Office                                                                                                                                                                  | Registered Office                                                                                                 |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|
| #1011, Solitaire Corporate Park<br>Building No. 10, 1 <sup>st</sup> Floor<br>Andheri Ghatkopar Link Road<br>Chakala, Andheri (E)<br>Mumbai - 400093<br>Tel: (91-22) 42254800 | 6 Lad Colony,<br>Y.N. Road,<br>Indore - 452003, (M.P.)<br>Tel: (91-731) 4217100/101<br>CIN: L66120MP1992PLC007182 |

| Stock Rating Scale | Absolute Return |
|--------------------|-----------------|
| BUY                | >20%            |
| ACCUMULATE         | 12% to 20%      |
| HOLD               | 5% to 12%       |
| NEUTRAL            | -5% to 5%       |
| REDUCE             | -5% to -12%     |
| SELL               | <-12%           |

| Research Analyst<br>Registration No. | Contact                 | Website                                                            | Email Id                                                                             |
|--------------------------------------|-------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------------------------|
| INH000002764                         | SMS: 'Arihant' to 56677 | <a href="http://www.arihantcapital.com">www.arihantcapital.com</a> | <a href="mailto:instresearch@arihantcapital.com">instresearch@arihantcapital.com</a> |

## Arihant Capital Markets Ltd.

1011, Solitaire Corporate park, Building No. 10, 1st Floor,  
Andheri Ghatkopar Link Road, Chakala, Andheri (E)  
Tel. 022-42254800

**Disclaimer:** This disclosure statement is provided in compliance with the SEBI Research Analyst Regulations, 2014. Arihant Capital Markets Limited (ACML) is a registered stockbroker, merchant banker, and research analyst under SEBI, and is also a Point of Presence with the Pension Fund Regulatory and Development Authority (PFRDA). ACML is registered with SEBI with Research Analyst Registration Number INH000002764, Stock Broker Registration Number INZ000180939, and is a Trading Member with NSE, BSE, MCX, NCDEX, and a Depository Participant with CDSL and NSDL.

ACML and its associates may have business relationships, including investment banking, with companies covered by its Investment Research Department. The analysts of ACML, and their associates, are prohibited from holding a financial interest in securities or derivatives of companies they cover, though they may hold stock in the companies they analyze. The recommendations provided by ACML's research team are based on technical and derivative analysis and may differ from fundamental research reports.

ACML confirms that neither it nor its associates have a financial interest or material conflict concerning the companies covered in the research report at the time of publication. Furthermore, ACML, its analysts, and their relatives have no ownership greater than 1% in the subject companies as of the month prior to publication. ACML guarantees that the compensation for its research analysts is not influenced by specific securities or transactions.

ACML affirms that neither the analyst nor the company has served as an officer, director, employee, or engaged in market-making activities for any of the subject companies. Additionally, the research report does not reflect any conflict of interest and is not influenced by specific recommendations made. Neither ACML nor its analysts have received compensation for investment banking or brokerage services from the subject companies in the last 12 months.

The views expressed in this report are those of the analysts and are independent of the proprietary trading desk of ACML, which operates separately to maintain an unbiased stance. Analysts comply with SEBI Regulations when offering recommendations or opinions through public media. The report is intended for informational purposes only and is not an offer or solicitation for the purchase or sale of securities.

This report, which is confidential, may not be reproduced or shared without written consent from ACML. It is based on publicly available data believed to be reliable but has not been independently verified, and no guarantees are made about its accuracy. All opinions and information contained in the report are subject to change without notice.

ACML disclaims liability for any losses resulting from reliance on this report. The report does not constitute an offer to buy or sell securities, and ACML is not responsible for the risks involved in investments. ACML and its affiliates may have positions in the securities discussed or hold other financial interests in them.

The distribution of this report in certain jurisdictions may be restricted by law, and the report is not intended for distribution where it would violate local laws. Investors are advised to consider their financial position, risk tolerance, and investment objectives before engaging in transactions, particularly in high-risk financial products such as derivatives.

ACML reserves the right to modify this disclosure statement without prior notice. The report has been prepared using publicly available information and internally developed data, though ACML does not guarantee its completeness or accuracy. Historical price data for securities can be accessed via official exchanges like NSE or BSE.

ACML and its affiliates may conduct proprietary transactions or investment banking services for the companies mentioned in this report. In compliance with SEBI regulations, ACML maintains comprehensive records of research reports, recommendations, and the rationale for those recommendations, which are preserved for at least five years. An annual compliance audit is conducted by a member of the ICAI or ICSI to ensure adherence to applicable regulations. This report is issued in accordance with applicable SEBI regulations and does not guarantee future performance or returns.

**Arihant Capital Markets Ltd.**

1011, Solitaire Corporate park, Building No. 10, 1st Floor,  
Andheri Ghatkopar Link Road, Chakala, Andheri (E)  
Tel. 022-42254800

---

Abhishek Jain  
Head of Research  
[Abhishek.jain@arihantcapital.com](mailto:Abhishek.jain@arihantcapital.com)

---